Biotech Values

[DewDiligence]

More notes from GILD CC:

GS9190 in HCV: dosing resumed in phase-1b trial at 40mg to ascertain the QT-prolongation before deciding whether to proceed to phase-2.

Elvitegravir in HIV: co-formulation with Truvada and a proprietary boosting agent called GS9350 has been achieved. If GS9350 passes monotherapy safety studies, it will supersede ritonavir as the boosting agent of choice for further development of elvitegravir.